Abstract
The 2019 coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 virus, caused a worldwide pandemic in 2020 and is the most urgent health issue worldwide. In this review, we highlight the details of Food and Drug Administration-Emergency Use Authorizations approved diagnostics kits, focusing on the similarities and differences. It is essential to understand the currently available options and the advantages and disadvantages each provides to select the appropriate products that maximize the testing efficiency. We believe this work will provide a holistic evaluation of the current COVID-19 diagnostic resources, including variations across the countries, and guide developing novel diagnostic techniques to improve and optimize the current testing options.
Keywords: COVID-19; FDA-EUA; molecular diagnostics; multicountry analysis; serological diagnostics.
【저자키워드】 COVID-19, molecular diagnostics, FDA-EUA, multicountry analysis, serological diagnostics., 【초록키워드】 coronavirus, Variation, diagnostic, drug, virus, diagnostics, Health, 2019 coronavirus disease, molecular, serological, food, similarity, Efficiency, disadvantage, acute respiratory syndrome, worldwide pandemic, authorization, resources, highlight, IMPROVE, caused, approved, provide, 【제목키워드】 technique,